Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.

Trial Profile

Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications Acquired immunodeficiency syndrome
  • Focus Pharmacokinetics
  • Sponsors Elea
  • Most Recent Events

    • 11 Apr 2016 New trial record
    • 06 Apr 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics
    • 06 Apr 2016 Primary endpoint (Area Under the Curve [AUC]) has been met, as per the results published in the International Journal of Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top